Free Trial
NASDAQ:RGLS

Regulus Therapeutics (RGLS) Stock Price, News & Analysis

Regulus Therapeutics logo
$8.16 0.00 (0.00%)
As of 06/25/2025

About Regulus Therapeutics Stock (NASDAQ:RGLS)

Key Stats

Today's Range
$8.16
$8.16
50-Day Range
$7.87
$8.30
52-Week Range
$0.83
$8.35
Volume
N/A
Average Volume
1.02 million shs
Market Capitalization
$564.92 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$8.50
Consensus Rating
Hold

Company Overview

Regulus Therapeutics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
39th Percentile Overall Score

RGLS MarketRank™: 

Regulus Therapeutics scored higher than 39% of companies evaluated by MarketBeat, and ranked 791st out of 936 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Regulus Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.29, and is based on 2 buy ratings, 5 hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Regulus Therapeutics has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about Regulus Therapeutics' stock forecast and price target.
  • Earnings Growth

    Earnings for Regulus Therapeutics are expected to decrease in the coming year, from ($0.88) to ($1.38) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Regulus Therapeutics is -11.18, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Regulus Therapeutics is -11.18, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Regulus Therapeutics has a P/B Ratio of 6.97. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about Regulus Therapeutics' valuation and earnings.
  • Percentage of Shares Shorted

    3.07% of the float of Regulus Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Regulus Therapeutics has a short interest ratio ("days to cover") of 0.7, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Regulus Therapeutics has recently decreased by 15.79%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Regulus Therapeutics does not currently pay a dividend.

  • Dividend Growth

    Regulus Therapeutics does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    3.07% of the float of Regulus Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Regulus Therapeutics has a short interest ratio ("days to cover") of 0.7, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Regulus Therapeutics has recently decreased by 15.79%, indicating that investor sentiment is improving significantly.
    • Insider Buying vs. Insider Selling

      In the past three months, Regulus Therapeutics insiders have bought more of their company's stock than they have sold. Specifically, they have bought $95,880.00 in company stock and sold $0.00 in company stock.

    • Percentage Held by Insiders

      Only 4.35% of the stock of Regulus Therapeutics is held by insiders.

    • Percentage Held by Institutions

      92.38% of the stock of Regulus Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

    • Read more about Regulus Therapeutics' insider trading history.
    Receive RGLS Stock News and Ratings via Email

    Sign-up to receive the latest news and ratings for Regulus Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

    RGLS Stock News Headlines

    Novartis completes acquisition of Regulus Therapeutics
    AI Frenzy Could Send ‘EarnPhone’ Soaring
    The hidden fuel behind AI? Your phone. Billions of data points — from your clicks, swipes, scrolls, and searches — are feeding the next wave of AI innovation. Big Tech is harvesting it. Mode Mobile is giving it back to you. They are creating a user-powered data economy that shares the upside, and +50M users have already generated +$325M in earnings. This isn't a theory… Mode’s 32,481% revenue growth from 2019-2022 landed them the #1 spot on Deloitte’s 2023 list of fastest growing companies in software, and they’ve secured the Nasdaq ticker $MODE ahead of a potential IPO. The offering could close any moment now. AI breakthroughs are everywhere, but these models need your data to survive. Invest in the company that allows you to share in the profits from yours.
    Regulus Therapeutics Inc.
    See More Headlines

    RGLS Stock Analysis - Frequently Asked Questions

    Regulus Therapeutics' stock was trading at $1.58 at the beginning of the year. Since then, RGLS shares have increased by 416.5% and is now trading at $8.16.

    Regulus Therapeutics Inc. (NASDAQ:RGLS) announced its earnings results on Thursday, May, 8th. The biopharmaceutical company reported ($0.15) EPS for the quarter, beating the consensus estimate of ($0.29) by $0.14.

    Regulus Therapeutics's stock reverse split before market open on Wednesday, June 29th 2022.The 1-10 reverse split was announced on Wednesday, June 29th 2022. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, June 29th 2022. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

    Shares of RGLS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

    Based on aggregate information from My MarketBeat watchlists, some other companies that Regulus Therapeutics investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Broadcom (AVGO), Adobe (ADBE), ServiceNow (NOW) and Eli Lilly and Company (LLY).

    Company Calendar

    Last Earnings
    5/08/2025
    Today
    7/28/2025
    Next Earnings (Estimated)
    8/06/2025
    Fiscal Year End
    12/31/2025

    Industry, Sector and Symbol

    Stock Exchange
    NASDAQ
    Sector
    Medical
    Industry
    MED - DRUGS
    Sub-Industry
    Biotechnology
    Current Symbol
    NASDAQ:RGLS
    CIK
    1505512
    Fax
    N/A
    Employees
    30
    Year Founded
    N/A

    Price Target and Rating

    High Price Target
    $11.00
    Low Price Target
    $7.00
    Potential Upside/Downside
    +4.2%
    Consensus Rating
    Hold
    Rating Score (0-4)
    2.29
    Research Coverage
    7 Analysts

    Profitability

    EPS (Trailing Twelve Months)
    ($0.73)
    Trailing P/E Ratio
    N/A
    Forward P/E Ratio
    N/A
    P/E Growth
    N/A
    Net Income
    -$46.36 million
    Net Margins
    N/A
    Pretax Margin
    N/A
    Return on Equity
    -57.53%
    Return on Assets
    -53.26%

    Debt

    Debt-to-Equity Ratio
    N/A
    Current Ratio
    16.31
    Quick Ratio
    16.31

    Sales & Book Value

    Annual Sales
    N/A
    Price / Sales
    N/A
    Cash Flow
    N/A
    Price / Cash Flow
    N/A
    Book Value
    $1.17 per share
    Price / Book
    6.97

    Miscellaneous

    Outstanding Shares
    69,230,000
    Free Float
    66,222,000
    Market Cap
    $564.92 million
    Optionable
    Optionable
    Beta
    0.35

    Social Links

    7 Energy Stocks to Buy and Hold Forever Cover

    With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

    Get This Free Report

    This page (NASDAQ:RGLS) was last updated on 7/28/2025 by MarketBeat.com Staff
    From Our Partners